FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth

Breast Cancer Research

Volumn 17, Issue 1, 2015, Pages

  Tancioni, Isabelle ^a   Miller, Nichol ^a,b   Uryu, Sean ^a   Lawson, Christine ^a   Jean, Christine ^a,c   Chen, Xiao Lei ^a   Kleinschmidt, Elizabeth G ^a   Schlaepfer, David D ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b PFIZER INC   (United States)

^c CANCER RESEARCH CENTER OF TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MERLIN; METHYLCELLULOSE; NUCLEAR PROTEIN; NUCLEOLIN; NUCLEOPHOSMIN; NUCLEOSTEMIN; PHOSPHOSPECIFIC ANTIBODY; PROTEIN KINASE B; SHORT HAIRPIN RNA; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; GNL3 PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; PROTEIN KINASE INHIBITOR; RAPAMYCIN; SMALL INTERFERING RNA;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CARCINOMA CELL; CELL FRACTIONATION; CELLS; CONTROLLED STUDY; DNA SEQUENCE; ENZYME ACTIVITY; ENZYME LOCALIZATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC50; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MCF 7 CELL LINE; MESOTHELIOMA; MOUSE; NONHUMAN; NUCLEOLUS; OVARY CARCINOMA; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR SPHEROID; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PROTEIN TRANSPORT; RNA INTERFERENCE; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR STEM CELL ASSAY; TUMOR VOLUME;

ANIMALS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GTP-BINDING PROTEINS; HUMANS; MICE; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SIROLIMUS; SPHEROIDS, CELLULAR; TUMOR BURDEN; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 84928571477     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-015-0551-x     Document Type: Article

References (52)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
2. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 2007;7:659-72.
3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-34.
4. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591-602.
5. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9-22.
6. Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14:598-610.
7. Lark AL, Livasy CA, Dressler L, Moore DT, Millikan RC, Geradts J, et al. High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol. 2005;18:1289-94.
8. Yom CK, Noh DY, Kim WH, Kim HS. Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer. Breast Cancer Res Treat. 2011;128:647-55.
9. Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, Chang J, et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res. 2000;6:2417-23.
10. Theocharis SE, Klijanienko JT, Padoy E, Athanassiou S, Sastre-Garau XX. Focal adhesion kinase (FAK) immunocytochemical expression in breast ductal invasive carcinoma (DIC): correlation with clinicopathological parameters and tumor proliferative capacity. Med Sci Monit. 2009;15:BR221-6.
11. Provenzano PP, Inman DR, Eliceiri KW, Beggs HE, Keely PJ. Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am J Pathol. 2008;173:1551-65.
12. Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLean GW, Frame MC, et al. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci U S A. 2007;104:20302-7.
13. Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, et al. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res. 2009;69:466-74.
14. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest. 2009;119:252-66.
15. Walsh C, Tanjoni I, Uryu S, Tomar A, Nam JO, Luo H, et al. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther. 2010;9:778-90.
16. Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, et al. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol Ther. 2010;9:764-77.
17. Ward KK, Tancioni I, Lawson C, Miller NL, Jean C, Chen XL, et al. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis. 2013;30:579-94.
18. Shah NR, Tancioni I, Ward KK, Lawson C, Chen XL, Jean C, et al. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol. 2014;134:104-11.
19. Tancioni I, Uryu S, Sulzmaier FJ, Shah NR, Lawson C, Miller NL, et al. FAK Inhibition Disrupts a beta5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth. Mol Cancer Ther. 2014;13:2050-61.
20. Wendt MK, Smith JA, Schiemann WP. Transforming growth factor-beta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene. 2010;29:6485-98.
21. Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, et al. Merlin deficiency predicts for FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Trans Med. 2014;6:237ra68.
22. Lim ST, Chen XL, Lim Y, Hanson DA, Vo TT, Howerton K, et al. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell. 2008;29:9-22.
23. Luo SW, Zhang C, Zhang B, Kim CH, Qiu YZ, Du QS, et al. Regulation of heterochromatin remodelling and myogenin expression during muscle differentiation by FAK interaction with MBD2. EMBO J. 2009;28:2568-82.
24. Lim ST, Miller NL, Chen XL, Tancioni I, Walsh CT, Lawson C, et al. Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. J Cell Biol. 2012;197:907-19.
25. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755-68.
26. Boisvert FM, van Koningsbruggen S, Navascues J, Lamond AI. The multifunctional nucleolus. Nat Rev Mol Cell Biol. 2007;8:574-85.
27. Hein N, Hannan KM, George AJ, Sanij E, Hannan RD. The nucleolus: an emerging target for cancer therapy. Trends Mol Med. 2013;19:643-54.
28. Tsai RY, McKay RD. A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes Dev. 2002;16:2991-3003.
29. Tsai RY. Turning a new page on nucleostemin and self-renewal. J Cell Sci. 2014;127:3885-91.
30. Okamoto N, Yasukawa M, Nguyen C, Kasim V, Maida Y, Possemato R, et al. Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci U S A. 2011;108:20388-93.
31. Lin T, Meng L, Li Y, Tsai RY. Tumor-initiating function of nucleostemin-enriched mammary tumor cells. Cancer Res. 2010;70:9444-52.
32. Kobayashi T, Masutomi K, Tamura K, Moriya T, Yamasaki T, Fujiwara Y, et al. Nucleostemin expression in invasive breast cancer. BMC Cancer. 2014;14:1-9.
33. Tsai RY, McKay RD. A multistep, GTP-driven mechanism controlling the dynamic cycling of nucleostemin. J Cell Biol. 2005;168:179-84.
34. Huang M, Itahana K, Zhang Y, Mitchell BS. Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin. Cancer Res. 2009;69:3004-12.
35. Lo D, Dai MS, Sun XX, Zeng SX, Lu H. Ubiquitin- and MDM2 E3 ligase-independent proteasomal turnover of nucleostemin in response to GTP depletion. J Biol Chem. 2012;287:10013-20.
36. Huang M, Whang P, Chodaparambil JV, Pollyea DA, Kusler B, Xu L, et al. Reactive oxygen species regulate nucleostemin oligomerization and protein degradation. J Biol Chem. 2011;286:11035-46.
37. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res. 2008;68:1935-44.
38. Andersen JS, Lyon CE, Fox AH, Leung AK, Lam YW, Steen H, et al. Directed proteomic analysis of the human nucleolus. Curr Biol. 2002;12:1-11.
39. Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19:197-208.
40. Stokes JB, Adair SJ, Slack-Davis JK, Walters DM, Tilghman RW, Hershey ED, et al. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011;10:2135-45.
41. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007;282:14845-52.
42. Ma H, Pederson T. Nucleophosmin is a binding partner of nucleostemin in human osteosarcoma cells. Mol Biol Cell. 2008;19:2870-5.
43. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926-45.
44. Cabrita MA, Jones LM, Quizi JL, Sabourin LA, McKay BC, Addison CL. Focal adhesion kinase inhibitors are potent anti-angiogenic agents. Mol Oncol. 2011;5:517-26.
45. Beck HC, Gosau M, Kristensen LP, Morsczeck C. A site-specific phosphorylation of the focal adhesion kinase controls the formation of spheroid cell clusters. Neurochem Res. 2014;39:1199-205.
46. Albasri A, Fadhil W, Scholefield JH, Durrant LG, Ilyas M. Nuclear expression of phosphorylated focal adhesion kinase is associated with poor prognosis in human colorectal cancer. Anticancer Res. 2014;34:3969-74.
47. Lee SB, Xuan Nguyen TL, Choi JW, Lee KH, Cho SW, Liu Z, et al. Nuclear Akt interacts with B23/NPM and protects it from proteolytic cleavage, enhancing cell survival. Proc Natl Acad Sci U S A. 2008;105:16584-9.
48. Iadevaia V, Zhang Z, Jan E, Proud CG. mTOR signaling regulates the processing of pre-rRNA in human cells. Nucleic Acids Res. 2012;40:2527-39.
49. Golubovskaya VM, Ylagan L, Miller A, Hughes M, Wilson J, Wang D, et al. High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype. BMC Cancer. 2014;14:769.
50. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011;13:224.
51. Broad-Novartis Cancer Cell Line Encyclopedia. http://www.broadinstitute.org/ccle .
52. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515-27.